Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Background: The COMPASSION-15 clinical trial demonstrated that cadonilimab plus chemotherapy significantly improved clinical benefits in human epidermal growth factor receptor 2-negative (HER2−) advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Objectives: This study investigated...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shixian Liu, Kaixuan Wang, Ruixue Wang, Hao Chen, Ziming Wan, Lei Dou, Shunping Li
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-08-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/17562848251366946
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Zhifeng Zhou, et al.
Published: (2025-05-01)

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01)

Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer
by: Longfeng Zhang, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
by: Liangliang Zou, et al.
Published: (2025-05-01)

Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5
by: Yalan Zhang, et al.
Published: (2025-08-01)

Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial
by: Hailong Jin, et al.
Published: (2025-07-01)

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
by: Genlin Lu, et al.
Published: (2025-01-01)

Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial
by: Kun Yang, et al.
Published: (2024-12-01)

First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials
by: Yuxuan Lin, et al.
Published: (2025-05-01)

Cadonilimab combined with trastuzumab and chemotherapy for HER2-positive gastric cancer with bone marrow metastasis and DIC: a case report and literature review
by: Meijing Chen, et al.
Published: (2025-06-01)

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
by: Run-Cong Nie, et al.
Published: (2025-02-01)

First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Jianying Lei, et al.
Published: (2024-11-01)

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration
by: Du Feng, et al.
Published: (2024-12-01)

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial
by: Funda Meric-Bernstam, et al.
Published: (2025-05-01)

Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model
by: Wenwei Yang, et al.
Published: (2025-06-01)

Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01)

Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study
by: Sarbajit Mukherjee, et al.
Published: (2025-04-01)

Meningeal Carcinomatosis: A Metastasis from Gastroesophageal Junction Adenocarcinoma
by: Tanya Dam, et al.
Published: (2013-01-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy in gastric cancer and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of single-arm studies
by: Jun Leng, et al.
Published: (2025-08-01)

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial
by: Xiangyu Meng, et al.
Published: (2025-07-01)

Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy
by: Yong Liu, et al.
Published: (2024-12-01)

Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes
by: Penghui Liu, et al.
Published: (2025-08-01)

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
by: Z.A. Wainberg, et al.
Published: (2024-12-01)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
by: Yan Wang, et al.
Published: (2022-03-01)

Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study
by: Aziz Zaanan, et al.
Published: (2025-07-01)

Digital pathology-based artificial intelligence model to predict microsatellite instability in gastroesophageal junction adenocarcinomas
by: Zhenqian Li, et al.
Published: (2025-08-01)

A case report and analysis of skin metastasis of adenocarcinoma of gastroesophageal junction and its therapeutic outcome
by: LI Hao, DENG Jin, LIU Peihua, ZHANG Quanyong, CAI Zhai
Published: (2025-06-01)

Laparoscopic curative resection following perioperative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel and its influence on Claudin18.2 expression in advanced gastric or gastroesophageal junction adenocarcinoma: a two-case report
by: Tohru Takahashi, et al.
Published: (2025-04-01)

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis
by: Xiaoying Ji, et al.
Published: (2025-03-01)

Increasing Incidence of Adenocarcinoma of the Gastroesophageal Junction and Distal Stomach in Canada – An Epidemiological Study from 1964 to 2002
by: Jeremy R Parfitt, et al.
Published: (2006-01-01)

Deciphering the dual role of autophagy in gastric cancer and gastroesophageal junction cancer: from tumor suppression to cancer progression
by: Lili Lei, et al.
Published: (2025-06-01)

Her2+ and b-HCG Producing Undifferentiated Gastric Adenocarcinoma
by: Sahar Eivaz-Mohammadi, et al.
Published: (2014-01-01)

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
by: Vincenzo Nasca, et al.
Published: (2025-04-01)

A rare case of synchronous management of gastroesophageal junction adenocarcinoma and renal cell carcinoma: is it just another oesophagectomy?
by: Natasha Hasemaki, et al.
Published: (2024-09-01)

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
by: Yiling Ding, et al.
Published: (2025-12-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma
by: A. Mirza, et al.
Published: (2013-01-01)